Identification of potential DAMPs released by necroptosis in estrogen-receptor positive breast cancer cells and their effect on macrophage differentiation

Abstract

Aim:Mutations in key regulators of apoptosis have necessitated exploring the alternative cell death pathways like necroptosis in breast cancer (BC). Necroptosis is immunogenic due to the release of damage-associated molecular patterns (DAMPs) into extracellular environment, which can trigger pro- or anti-tumor immune responses. Inducing necroptosis in estrogen receptor-positive (ER+) BC cells leads to the release of DAMPs, which can influence macrophages polarisation within the tumor microenvironment. The study aims to identify and characterize the DAMPs released from ER+ BC cells after necroptosis induction and to investigate their effects on macrophage properties.

Methods:Necroptosis was induced by treating T-47D cells with Z-VAD-FMK and TNF-α (24 hours). The culture medium was collected as induction medium (IM). Necrostatin-1 alongside Z-VAD-FMK and TNF-α was added to inhibit necroptosis, the culture medium was collected as inhibition medium (InM) and used as a negative control for necroptosis. IM also referred as conditioned medium (CM), was analyzed using LC-MS/MS for the identification of DAMPs. THP-1 macrophages were incubated with the CM (24 hours), and their differentiation into M1 or M2 subtypes was assessed using qPCR, by evaluating the expression of specific M1 and M2 markers.

Results:A total of 35 unique proteins with potential DAMP activity were identified in the IM. Functional and pathway analyses using PANTHER and DAVID revealed their involvement in immune regulation, metabolism, stress responses, and key pathways such as glycolysis, signaling, and inflammation. These proteins were primarily intracellular or secretory and included cytoskeletal components, chaperones, and binding modulators. Furthermore, IM treatment promoted THP-1 monocyte differentiation into both M1 and M2 macrophage subtypes.

Conclusions:These findings highlight the role of necroptosis in generating DAMPs, which can modulate macrophage differentiation within the BC microenvironment. The identified DAMPs hold potential for further investigation as prognostic or predictive biomarkers and therapeutic targets in future studies.

Keywords

Breast cancer / ER positive / necroptosis / DAMPs / M1 and M2 macrophages

References

[1] Linkermann A, Stockwell BR, Krautwald S, Anders H. Regulated cell death and inflammation: an autoamplification loop causes organ failure. Nat Rev Immunol. 2014; 14: 759-67.

[2] Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018; 25: 486-541.

[3] Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005; 1: 112-9.

[4] Galluzzi L, Kroemer G. Necroptosis: a specialized pathway of programmed necrosis. Cell. 2008; 135: 1161-3.

[5] Thakur B, Kumar Y, Bhatia A. Programmed necrosis and its role in management of breast cancer. Pathol Res Pract. 2019; 215: 152652.

[6] Criscitiello C, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, et al. Immune approaches to the treatment of breast cancer, around the corner? Breast Cancer Res. 2014; 16: 204.

[7] Krysko O, Aaes TL, Bachert C, Vandenabeele P, Krysko DV. Many faces of DAMPs in cancer therapy. Cell Death Dis. 2013; 4: e631.

[8] Sangiuliano B, Pérez NM, Moreira DF, Belizário JE. Cell death-associated molecular-pattern molecules: inflammatory signaling and control. Mediators Inflamm. 2014; 2014: 821043.

[9] Fucikova J, Moserova I, Urbanova L, Bezu L, Kepp O, Cremer I, et al. Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Front Immunol. 2015; 6: 402.

[10] Vrakas CN, O’Sullivan RM, Evans SE, Ingram DA, Jones CB, Phuong T, et al. The Measure of DAMPs and a role for S100A8 in recruiting suppressor cells in breast cancer lung metastasis. Immunol Invest. 2015; 44: 174-88.

[11] Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ. 2014; 21: 69-78.

[12] Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2020; 20: 95-112.

[13] Thakur B, Saha L, Bhatia A. Relative refractoriness of breast cancer cells to tumour necrosis factor-α induced necroptosis. Clin Exp Pharmacol Physiol. 2022; 49: 1294-306.

[14] Thakur B, Saha L, Dahiya D, Bhatia A. Effect of aspirin on the TNF-α-mediated cell survival and death pathways in breast cancer. J Basic Clin Physiol Pharmacol. 2022; 34: 91-102.

[15] Lee K, Lee H, Han D, Moon WK, Kim K, Oh HJ, et al. Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer. Breast Cancer Res. 2020; 22: 130.

[16] Lalaoui N, Merino D, Giner G, Vaillant F, Chau D, Liu L, et al. Targeting triple-negative breast cancers with the Smac-mimetic birinapant. Cell Death Differ. 2020; 27: 2768-80.

[17] Thakur B, Verma R, Bhatia A. Mutations in Necroptosis-Related Genes Reported in Breast Cancer: A Cosmic and Uniport Database-Based Study. Clin Breast Cancer. 2024;S1526-820900356-2.

[18] Koo G, Morgan MJ, Lee D, Kim W, Yoon J, Koo JS, et al. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res. 2015; 25: 707- 25.

[19] Khorsandi L, Orazizadeh M, Niazvand F, Abbaspour MR, Mansouri E, Khodadadi A. Quercetin induces apoptosis and necroptosis in MCF-7 breast cancer cells. Bratisl Lek Listy. 2017; 118: 123-8.

[20] Shahsavari Z, Karami-Tehrani F, Salami S. Targeting Cell Necroptosis and Apoptosis Induced by Shikonin via Receptor Interacting Protein Kinases in Estrogen Receptor Positive Breast Cancer Cell Line, MCF-7. Anticancer Agents Med Chem. 2018; 18: 245-54.

[21] Murao A, Aziz M, Wang H, Brenner M, Wang P. Release mechanisms of major DAMPs. Apoptosis. 2021; 26: 152-62.

[22] Land WG, Agostinis P, Gasser S, Garg AD, Linkermann A. Transplantation and Damage-Associated Molecular Patterns (DAMPs). Am J Transplant. 2016; 16: 3338-61.

[23] Denning N, Aziz M, Gurien SD, Wang P. DAMPs and NETs in Sepsis. Front Immunol. 2019; 10: 2536.

[24] Wu Chuang A, Kepp O, Kroemer G, Bezu L. Endoplasmic reticulum stress in the cellular release of damage-associated molecular patterns. Int Rev Cell Mol Biol. 2020; 350: 1-28.

[25] Rigiracciolo DC, Cirillo F, Talia M, Muglia L, Gutkind JS, Maggiolini M, et al. Focal Adhesion Kinase Fine Tunes Multifaced Signals toward Breast Cancer Progression. Cancers (Basel). 2021; 13: 645.

[26] Cai Z, Zhang A, Choksi S, Li W, Li T, Zhang X, et al. Activation of cell-surface proteases promotes necroptosis, inflammation and cell migration. Cell Res. 2016; 26: 886-900.

[27] Zhang X, Yin M, Zhang L. Keratin 6, 16 and 17-Critical Barrier Alarmin Molecules in Skin Wounds and Psoriasis. Cells. 2019; 8: 807.

[28] Díaz-Ramos A, Roig-Borrellas A, García-Melero A, López-Alemany R. α-Enolase, a multifunctional protein: its role on pathophysiological situations. J Biomed Biotechnol. 2012; 2012: 156795.

[29] Tu S, Chang C, Chen C, Tam K, Wang Y, Lee C, et al. Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010; 121: 539-53.

[30] Seny Dd, Cobraiville G, Charlier E, Neuville S, Lutteri L, Goff CL, et al. Apolipoprotein-A1 as a damage-associated molecular patterns protein in osteoarthritis: ex vivo and in vitro pro-inflammatory properties. PLoS One. 2015; 10: e0122904.

[31] Kang N, Ji Z, Li Y, Gao J, Wu X, Zhang X, et al. Metabolite-derived damage-associated molecular patterns in immunological diseases. FEBS J. 2024; 291: 2051-67.

[32] Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately? Blood. 2009; 114: 2367-74.

[33] Wang H, Kim SJ, Lei Y, Wang S, Wang H, Huang H, et al. Neutrophil extracellular traps in homeostasis and disease. Signal Transduct Target Ther. 2024; 9: 235.

[34] Ahrens S, Zelenay S, Sancho D, Hanč P, Kjær S, Feest C, et al. F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity. 2012; 36: 635-45.

[35] Zhang JG, Czabotar PE, Policheni AN, Caminschi I, Wan SS, Kitsoulis S, et al. The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. Immunity. 2012; 36: 646-57.

[36] Nami B, Wang Z. Genetics and Expression Profile of the Tubulin Gene Superfamily in Breast Cancer Subtypes and Its Relation to Taxane Resistance. Cancers (Basel). 2018; 10: 274.

[37] Xia L, Xiao X, Liu WL, Song Y, Liu TJJ, Li YJ, et al. Coactosin-like protein CLP/Cotl1 suppresses breast cancer growth through activation of IL-24/PERP and inhibition of non-canonical TGFβ signaling. Oncogene. 2018; 37: 323-31.

[38] Huerta-Reyes M, Maya-Núñez G, Pérez-Solis MA, López-Muñoz E, Guillén N, Olivo-Marin J, et al. Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs. Front Oncol. 2019; 9: 943.

[39] Aoudjit F, Vuori K. Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract. 2012; 2012: 283181.

[40] Calaf GM, Abarca-Quinones J. Ras protein expression as a marker for breast cancer. Oncol Lett. 2016; 11: 3637-42.

[41] Zhang W, Wang M, Ji C, Liu X, Gu B, Dong T. Macrophage polarization in the tumor microenvironment: Emerging roles and therapeutic potentials. Biomed Pharmacother. 2024; 177: 116930.

[42] Fagone P, Rosa MD, Palumbo M, Gregorio CD, Nicoletti F, Malaguarnera L. Modulation of heat shock proteins during macrophage differentiation. Inflamm Res. 2012; 61: 1131-9.

[43] Fearing BV, Dyke MEV. In vitro response of macrophage polarization to a keratin biomaterial. Acta Biomater. 2014; 10: 3136-44.

[44] Fréret M, Rottenberg P, Calbo S, Lequerré T, Vittecoq O. 08.02 Alpha-enolase promotes pro-inflammatory phenotype of monocytes-derived macrophages in vitro. Ann Rheum Dis. 2017; 76: A75.

[45] Wang S, Wang J, Chen Z, Luo J, Guo W, Sun L, et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis Oncol. 2024; 8: 31.